Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 700 across all filing types
Latest filing 2015-11-09 Director's Dealing
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2015-11-09 English
10-Q
Interim / Quarterly Report Q3 2015
2015-11-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 4, 2015, reporting the issuance of a press release announcing financial results for the quarter ended September 30, 2015. The text states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of the earnings information. The length of the document is 2910 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results, even though the full details are in the attached press release. Therefore, the appropriate classification is ER with high confidence.
2015-11-04 English
FORM 4
Director's Dealing
2015-11-04 English
FORM 4
Director's Dealing
2015-10-28 English
FORM 4
Director's Dealing
2015-10-20 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.